Pricing Log in Create free account
Friday 6 November 2026 Export PHG’s income statement to Excel — free account

Koninklijke Philips N.V.

PHG Healthcare Medical Devices

Koninklijke Philips N.V.’s revenue for fiscal 2025 (year ended December 2025) was $20.2 billion, up 3.47% from fiscal 2024.

Revenue
+0.55%
EPS
−85.0%
Free cash flow
+154.2%
Total debt
−4.96%

Quarter to September 2026, against a year earlier

30.38 0.13 −0.43%
Market cap
$29.8B
P/E
25.8×
Fwd P/E
11.2×
Dividend yield
3.33%
F-score
7/9
Altman Z
1.98
Beneish M
−2.68
Dividend safety
55/100
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 0.02%

Capital & Financial Ratios $m

Size
Market Cap 29,820.00
Revenue ttm 20,604.22
Net income ttm 1,076.14
Free cash flow ttm 2,116.65
Net debt Q 4,815.78
Valuation
P/E 25.76
Forward P/E 11.20
Price / sales 1.44
Forward P/S Powerpack
Price / FCF 14.06
Price / book 2.23
Financial health
Current ratio Q 1.33
Debt / equity Q 0.60
Interest coverage Q 1.96
Growth
Revenue growth Q +0.55% (above 0%: growing)
Operating income growth Q −50.62% (below 0%: shrinking)
EPS, this year +0.62%
EPS, next year A +0.97%
Revenue, next year A −99.58% (below 0%: weak)
EPS, past 5 yrs −6.51% (below 0%: weak)
EPS, next 5 yrs A +4.35%

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 1.7×, against a ten-year median of 1.5×; over the ten years it ranged from 0.7× in 2022 to 1.9× in 2018.
P/E against its own 10 years 64.93%
10-year low 10-year high
P/S against its own 10 years 76.60%
10-year low 10-year high
P/B against its own 10 years 58.16%
10-year low 10-year high
EV/Sales against its own 10 years 79.57%
10-year low 10-year high
EV/FCF against its own 10 years 47.17%
10-year low 10-year high

Dividends

Yield
3.33%
Annual rate
1.01
Payout ratio
86.6%
Growth, 2016–25
+1.16%/yr
  1. 0.87 ’16
  2. 0.87 ’17 +0
  3. 0.91 ’18 +5
  4. 0.93 ’19 +2
  5. 0.94 ’20 +1
  6. 1.00 ’21 +7
  7. 0.88 ’22 −12
  8. 0.00 ’24 −100
  9. 0.97 ’25
  10. 0.02 ’26e −98
paid forecast change on the year, %

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 2,075 2,675 3,253 3,224
Receivables 4,278 4,709 4,062 4,162
Inventory 3,778 3,461 3,247 3,918
Other 627 634 674 791
10,758 10,845 11,237 12,094
2023 2024 2025 Q'26
Payables 2,075 1,980 2,180 2,459
ST’ Debt — — — —
Other 4,033 4,425 2,977 3,298
8,969 8,815 8,496 9,103

Compound Annual Growth %

10y 5y 3y
Sales (2.84%) (1.99%) 2.42%
Cash Flow 0.23% (16.01%) 0.00%
Earnings 3.52% (5.67%) 0.00%
Book Value (0.51%) (1.77%) (3.87%)

Earnings Trends EPS, adjusted, against the consensus

Sep 2026 Estimate 0.37 Actual 0.46

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Sep 2025 0.37 0.37 Met by 0.00
Mar 2026 0.24 0.27 Beat by 0.03
Jun 2026 0.40 0.57 Beat by 0.17
Sep 2026 0.37 0.46 Beat by 0.09
Dec 2026 0.69 — Reports 9 February 2027

EPS $

Mar Jun Sep Dec Year
’26 0.19 0.47 0.03 — —
’25 0.08 0.28 0.22 0.48 1.05
’24 — 0.52 0.21 — (0.81)
’23 (0.80) 0.09 0.10 — (0.55)
’22 0.05 (0.02) (1.51) (1.66) (1.92)
’21 0.05 0.05 3.82 3.74 4.32
’20 0.04 0.25 0.43 1.21 1.47
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 4,570 5,069 5,056 — —
’25 4,316 4,924 5,029 5,908 20,177
’24 — 4,805 4,813 — 19,501
’23 4,473 4,874 4,866 — 19,664
’22 4,397 4,445 4,341 10,353 18,783
’21 4,614 5,097 4,901 10,340 20,297
’20 4,588 4,839 5,822 13,557 22,315
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 220 436 620 — —
’25 (983) 363 364 1,582 1,326
’24 — (88) — — 1,698
’23 — 367 — — 2,312
’22 — (567) — 383 (182)
’21 — 787 — 1,110 1,927
’20 — 772 — 2,563 3,172
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 33 259 440 — —
’25 (1,150) 173 173 1,385 580
’24 — (431) — — 980
’23 — 132 — — 1,712
’22 — (947) — 383 (1,013)
’21 — 405 — 1,110 1,064
’20 — 281 — 2,563 2,117
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

2.2
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Sep ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 27,129 20,097 21,401 21,820 22,315 20,297 18,783 19,664 19,501 20,177 20,604 (3.2%) 85 — — (99.6%)
Gross margin, % 43.29 46.01 47.20 45.55 44.95 41.78 40.35 40.99 43.13 45.18 46.43 +1.9 pt
EBT 1,537 1,556 1,775 1,712 1,702 602 (1,824) (569) 133 1,337 1,521 (1.5%)
EBT margin, % 5.67 7.74 8.29 7.85 7.63 2.97 (9.71) (2.90) 0.68 6.63 7.38 +1.0 pt
Net income 1,650 2,114 1,296 1,314 1,365 3,931 (1,691) (501) (755) 1,015 1,076 (5.3%)
Per share, $
Per share, $ Revenue 29.55 21.64 23.19 24.16 24.58 22.45 21.30 21.43 20.89 21.28 21.08 (3.6%)
Earnings 1.75 2.01 1.39 1.45 1.50 4.34 (1.92) (0.55) (0.81) 1.06 1.18 (5.4%)
Cash flow 2.30 2.28 2.28 2.52 3.49 2.13 (0.21) 2.52 1.82 1.40 2.92 (5.4%)
Capex (1.00) (0.83) (1.02) (1.21) (1.16) (0.96) (0.94) (0.65) (0.77) (0.79) (0.76) (2.7%)
Free cash flow 1.29 1.44 1.26 1.31 2.33 1.18 (1.15) 1.87 1.05 0.61 2.17 (8.0%)
Book value 16.28 14.63 15.50 15.66 14.98 18.94 15.87 14.23 13.96 13.11 13.67 (2.4%)
Shares, m 918 929 923 903 908 904 882 917 933 948 958 +0.4%
Valuation, ×
Valuation, × P/E 16.14 17.15 12.31 16.98 25.52 4.35 0.00 0.00 27.23 24.87 25.76 14.5
P/S 0.95 1.51 1.08 1.23 1.65 1.24 0.57 0.84 1.22 1.27 1.44 1.2
P/B 1.72 2.30 2.15 2.93 3.24 1.89 0.95 1.55 1.84 2.07 2.23 2.1
EV/Sales 1.01 1.63 1.15 1.34 1.75 1.43 0.84 1.11 1.51 1.50 1.68 1.3
EV/FCF 22.98 22.99 12.46 15.19 12.51 10.22 (655.53) (140.38) (23.53) 52.15 16.34 (67.1)
Cash, $m
Cash, $m Operating cash flow 2,107 2,114 2,102 2,275 3,172 1,927 (182) 2,312 1,698 1,326 2,857 (5.0%)
Capex (920) (773) (941) (1,095) (1,055) (864) (830) (600) (717) (746) (741) (2.3%)
Free cash flow 1,187 1,341 1,161 1,179 2,117 1,064 (1,013) 1,712 980 580 2,117 (7.6%)
Balance, $m
Balance, $m Working capital 3,986 3,675 1,924 2,779 3,989 3,427 2,450 1,789 2,030 2,741 2,990 (4.1%)
Net debt 1,643 2,313 1,496 3,935 2,712 4,859 6,284 5,539 5,022 4,592 4,816 +12.1%
Shareholders’ equity 14,948 13,590 14,310 14,140 13,595 17,125 13,995 13,054 13,032 12,434 13,362 (2.0%)
Returns, %
Returns, % ROA 4.57 5.82 4.34 4.29 4.38 11.50 (4.91) (1.57) (2.40) 3.27 3.49 (1.3) pt
ROIC 7.85 6.74 8.02 6.37 6.75 1.86 (4.96) (0.42) 1.98 5.91 6.15 (1.9) pt
ROE 11.43 13.13 9.23 9.19 9.78 25.56 (10.89) (3.73) (5.82) 7.95 8.54 (3.5) pt
People
People Employees 113,678 73,951 77,400 80,495 81,592 78,189 77,233 69,656 66,678 65,340 — (6.0%)
Revenue/emp, $m 0.24 0.27 0.28 0.27 0.27 0.26 0.24 0.28 0.29 0.31 — +2.9%
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 5 Nov 2026

Koninklijke Philips N.V. vs peers in Medical Devices (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
BSX Boston Scientific Corporation $64.7B 18.7× 17.0× +1.44% (above 0%: growing) −21.57% (below 0%: shrinking) −25.30% (below 0%: shrinking) 66.72% 16.12% Compare
EW Edwards Lifesciences Corporation $58.1B 56.7× 36.5× +10.46% (above 0%: growing) +6.00% (above 0%: growing) −1.84% (below 0%: shrinking) 78.48% 17.44% Compare
GEHC GE HealthCare Technologies Inc. $37.9B 17.5× 15.5× +7.19% (above 0%: growing) +40.64% (above 0%: growing) +64.18% (above 0%: growing) 40.34% 14.58% Compare
DXCM DexCom, Inc. $31.5B 32.6× 31.8× +11.18% (above 0%: growing) 0.00% −52.93% (below 0%: shrinking) 64.29% 24.34% Compare
PHG Koninklijke Philips N.V. $29.8B 25.8× 11.2× +0.55% (above 0%: growing) −85.00% (below 0%: shrinking) +154.15% (above 0%: growing) 46.44% 3.76%
STE STERIS plc $24.8B 30.0× 25.1× +8.79% (above 0%: growing) +12.82% (above 0%: growing) +43.64% (above 0%: growing) 44.74% 18.53% Compare
ZBH Zimmer Biomet Holdings, Inc. $20.4B 26.9× 18.9× +3.07% (above 0%: growing) −13.45% (below 0%: shrinking) +29.77% (above 0%: growing) 71.18% 14.91% Compare
SNN Smith & Nephew SNATS, Inc. $13.4B 38.9× 18.9× +7.99% (above 0%: growing) −14.23% (below 0%: shrinking) +293.94% (above 0%: growing) 69.42% 0.00% Compare
GKOS Glaukos Corporation $13.0B — (loss-making) — (loss-making) +58.03% (above 0%: growing) n/m +411.22% (above 0%: growing) 85.23% 0.39% Compare
Median of peers $28.1B 30.0× 18.9× +8.39% 0.00% +36.71% 68.07% 15.52%

All 149 Medical Devices stocks →

Koninklijke Philips N.V. (PHG) Latest News

4 Nov

Impact 3 · · medtechdive.com
Impact 3 · · medicaldevice-network.com
Impact 3 · · GuruFocus.com

3 Nov

Impact 3 · · MarketBeat
Impact 3 · · AFP
Impact 3 · · Investing.com
Impact 3 · · AFP
Impact 3 · · GlobeNewswire

29 Oct

Impact 4 · · GlobeNewswire

27 Oct

Impact 4 · · PR Newswire

24 Oct

Impact 3 · · Simply Wall St.

20 Oct

Impact 4 · · GlobeNewswire

16 Oct

Impact 4 · · Simply Wall St.

15 Oct

Impact 4 · · GlobeNewswire
Impact 3 · · Business Wire

11 Oct

Impact 3 · · TIKR

10 Oct

Impact 3 · · Investing.com

8 Oct

Impact 4 · · Business Wire

5 Oct

Impact 4 · · Business Wire

1 Oct

Impact 3 · · Simply Wall St.

8 Sep

Impact 3 ·
Impact 3 ·

7 Sep

Impact 3 ·

4 Sep

Impact 3 ·

3 Sep

Impact 3 ·

2 Sep

Impact 3 · · TheStreet

1 Sep

Impact 4 ·

28 Aug

Impact 3 · · hospitalmanagement.net

27 Aug

Impact 3 ·
Impact 3 · · medtechdive.com

PHG metrics, ten years each

stockrow.com/PHG · Data as of Nov 5, 2026 · For information only; not investment advice. · © 2026 stockrow.com